Overview

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Trebananib